Tag: material

ROK Financial announces new loan pathways for pool and spa contractors heading into the 2025 season. By offering no credit check financing, fast approvals, and expanded loan ranges, the company addresses growing demand among small business owners with fair or poor credit histories. This initiative responds to the sharp rise in alternative lending searches and the increased pressure on contractors seeking reliable capital access as traditional banks tighten standards.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Centene To Contact Him Directly To Discuss Their Options

Contractors facing credit challenges in 2025 are fueling record demand for alternative financing, as ROK Financial expands business loan programs designed to keep projects funded and crews working nationwide.

NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Novo Nordisk A/S (NYSE:NVO), Altimmune, Inc. (NASDAQ:ALT), SelectQuote, Inc. (NYSE:SLQT) and Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Demand for the best bad credit business loan options in 2025 has reached record levels as small business owners search for alternatives to traditional bank financing. With higher interest rates and stricter underwriting cutting off access to capital, ROK Financial is expanding programs that include SBA loans, lines of credit, equipment financing, and working capital solutions. This surge reflects a broader national shift toward flexible lending models that prioritize speed, transparency, and accessibility for entrepreneurs facing credit challenges across industries.

SAN DIEGO, Aug. 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Charter Communications, Inc. (NASDAQ: CHTR) securities, including purchasers of call options or sellers of put options between July 26, 2024 and July 24, 2025, inclusive (the “Class Period”), have until October 14, 2025 to seek appointment as lead plaintiff of the Charter Communications class action lawsuit. Captioned Sandoval v. Charter Communications, Inc., No. 25-cv-06747 (S.D.N.Y.), the Charter Communications class action lawsuit charges Charter Communications and certain of Charter Communications’ top executives with violations of the Securities Exchange Act of 1934.

Learn how Honest Loans connects US borrowers to quick $1,000 online loans with a simple application process and flexible options.

An In-Depth 2025 Analysis of PurelyWHITE Deluxe Teeth Whitening Powder and Consumer Trends in Sensitivity-Free Oral Care

Not for distribution to United States newswire services or for dissemination in the United States

SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Gollapalli v. KinderCare Learning Companies, Inc., et al., No. 3:25-cv-01424 (D. Or.) has been filed and seeks to represent investors who purchased KinderCare (NYSE: KLC) common stock in or traceable to the company’s October 2024 IPO.

BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 12, 2025, the company issued inducement awards to Adam Craig, M.D., John Volpone and David Kirske under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”), consisting of (i) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 2,833,812 shares of X4’s common stock granted to Mr. Kirske. In addition, effective on August 14, 2025, the company issued additional inducement awards to Dr. Craig, Mr. Volpone and Mr. Kirske under the 2019 Inducement Plan, consisting of (i) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 352,800 shares of X4’s common stock granted to Mr. Kirske.

BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is proud to announce a major scientific milestone: the publication of Body Oxygen Homeostasis and Mitochondrial Function from Animal Models to Clinical Applications by Prof. Avraham Mayevsky, a key advisor to Bioxytran. This groundbreaking work dives deep into the science of oxygen regulation and mitochondrial health – revealing transformative insights that could redefine treatment for stroke, Alzheimer’s, and other critical conditions.

https://link.springer.com/book/10.1007/978-3-031-94113-9